Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice

Figures & data

Figure 1. Mechanism of action of bevacizumab [11].

Table 1. Original bevacizumab clinical trials distribution on the basis of therapeutic area.

Therapeutic area	Clinical trials count	Clinical trials count (%)
Ophthalmology	19	45
Oncology	18	43
Angiology	3	7
Infectious disease	2	5

Table 2. Original bevacizumab clinical trials distribution on the basis of phase.

Early Phase I	Phase I	Phase I/II	Phase II	Phase III	Phase IV	N/A
1	3	5	16	11	3	3

Figure 2. Original bevacizumab clinical trials distribution on the basis of blinding type.

Figure 3. Original bevacizumab clinical trials distribution on the basis of funding type.

Table 3. Distribution of clinical trials included in bevacizumab-biosimilars analysis.

Bevacizumab-biosimilar trials groups	Clinical trials count	Clinical trials count (%)
Group 1	16	23
Group 2	19	28
Group 3	33	49

Bachu RD, Abou-Dahech M, Balaji S, et al. Oncology biosimilars: new developments and future directions. Cancer Rep (Hoboken). 2022;5(11):e1720. Epub 2022 Oct 4. PMID: 36195576; PMCID: PMC9675387. doi: 10.1002/cnr2.1720.

 PubMedGoogle Scholar

Data availability statement

The authors confirm that the data supporting the findings of this study is available within the article.